LT3046412T - Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai - Google Patents

Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai

Info

Publication number
LT3046412T
LT3046412T LTEP14781761.3T LT14781761T LT3046412T LT 3046412 T LT3046412 T LT 3046412T LT 14781761 T LT14781761 T LT 14781761T LT 3046412 T LT3046412 T LT 3046412T
Authority
LT
Lithuania
Prior art keywords
antibodies
human
manufacture
produced
light chain
Prior art date
Application number
LTEP14781761.3T
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/030,424 external-priority patent/US20140013456A1/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3046412T publication Critical patent/LT3046412T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
LTEP14781761.3T 2013-09-18 2014-09-18 Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai LT3046412T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/030,424 US20140013456A1 (en) 2012-03-16 2013-09-18 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PCT/US2014/056285 WO2015042250A1 (en) 2013-09-18 2014-09-18 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Publications (1)

Publication Number Publication Date
LT3046412T true LT3046412T (lt) 2019-07-25

Family

ID=51663490

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14781761.3T LT3046412T (lt) 2013-09-18 2014-09-18 Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai

Country Status (25)

Country Link
EP (2) EP3549437B1 (lt)
JP (3) JP6621750B2 (lt)
KR (2) KR102150414B1 (lt)
CN (2) CN111019953A (lt)
AU (2) AU2014323527B2 (lt)
BR (1) BR112016005912A2 (lt)
CA (1) CA2922892C (lt)
CY (1) CY1121798T1 (lt)
DK (1) DK3046412T3 (lt)
ES (2) ES2738679T3 (lt)
HR (1) HRP20191233T1 (lt)
HU (1) HUE044747T2 (lt)
IL (2) IL244226B (lt)
LT (1) LT3046412T (lt)
MX (1) MX362904B (lt)
MY (1) MY191512A (lt)
PL (1) PL3046412T3 (lt)
PT (1) PT3046412T (lt)
RS (1) RS59003B1 (lt)
RU (2) RU2019121863A (lt)
SG (2) SG10201810825YA (lt)
SI (1) SI3046412T1 (lt)
SM (1) SMT201900487T1 (lt)
TR (1) TR201909967T4 (lt)
WO (1) WO2015042250A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
WO2020132557A1 (en) * 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
EP4075965A1 (en) * 2019-12-18 2022-10-26 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114568343B (zh) * 2022-03-11 2023-04-07 成都合拓创展生物科技有限公司 制备眼病模型的头具及其应用
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010054212A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US10106810B2 (en) 2009-07-16 2018-10-23 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN102803491A (zh) * 2010-01-21 2012-11-28 奥克西雷恩英国有限公司 用于在酵母细胞表面上展示多肽的方法和组合物
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
SI2480675T1 (sl) * 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
HRP20181811T1 (hr) * 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
SG11201401102VA (en) * 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
US20140013456A1 (en) * 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MY185881A (en) * 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences

Also Published As

Publication number Publication date
JP2016533768A (ja) 2016-11-04
TR201909967T4 (tr) 2019-07-22
SMT201900487T1 (it) 2019-11-13
WO2015042250A1 (en) 2015-03-26
JP6621750B2 (ja) 2019-12-18
KR20200103882A (ko) 2020-09-02
DK3046412T3 (da) 2019-07-15
ES2738679T3 (es) 2020-01-24
IL244226A0 (en) 2016-04-21
PL3046412T3 (pl) 2019-11-29
EP3549437A1 (en) 2019-10-09
CN105722387B (zh) 2020-01-17
KR20160049018A (ko) 2016-05-04
RU2694728C2 (ru) 2019-07-16
BR112016005912A2 (pt) 2017-09-26
RU2016114306A3 (lt) 2018-04-26
HRP20191233T1 (hr) 2019-10-18
PT3046412T (pt) 2019-07-16
WO2015042250A9 (en) 2016-04-28
JP2020078350A (ja) 2020-05-28
CA2922892C (en) 2022-06-14
JP2019068850A (ja) 2019-05-09
AU2014323527A1 (en) 2016-04-07
CY1121798T1 (el) 2020-07-31
ES2962489T3 (es) 2024-03-19
SG11201601272YA (en) 2016-03-30
EP3046412A1 (en) 2016-07-27
EP3549437B1 (en) 2023-10-25
IL244226B (en) 2019-02-28
CN105722387A (zh) 2016-06-29
RU2016114306A (ru) 2017-10-23
KR102150414B1 (ko) 2020-09-02
MX362904B (es) 2019-02-25
MY191512A (en) 2022-06-28
WO2015042250A4 (en) 2015-05-28
AU2014323527B2 (en) 2020-10-15
RU2019121863A (ru) 2019-08-29
RS59003B1 (sr) 2019-08-30
AU2021200228A1 (en) 2021-03-18
CA2922892A1 (en) 2015-03-26
SI3046412T1 (sl) 2019-08-30
HUE044747T2 (hu) 2019-11-28
CN111019953A (zh) 2020-04-17
MX2016003638A (es) 2016-07-21
HK1225913A1 (en) 2017-09-22
EP3046412B1 (en) 2019-04-10
IL264358A (en) 2019-02-28
EP3549437C0 (en) 2023-10-25
SG10201810825YA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
IL290972A (en) Anti-vista antibodies and fragments
LT3348140T (lt) Histidinu pakeisti lengvosios grandinės antikūnai ir genetiškai modifikuoti graužikai, išvesti jų gamybai
IL257563A (en) Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
LT3192812T (lt) Anti-cd3 antikūnai ir jų panaudojimo būdai
IL246287B (en) Fabs-in-tandem immunoglobulin and uses thereof
DK3083688T3 (da) Humane anti-cd40 humane antistoffer
LT3353212T (lt) Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
PL3406633T3 (pl) Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3071597T (lt) Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
SI3134127T1 (sl) Konjugati zdravil s protitelesi z visoko stopnjo zdravila
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
DK3480215T3 (da) Anti-HER2-antistof og konjugat deraf
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
CL2015003496A1 (es) Anticuerpos teicoicos anti-pared y conjugados.
IL262776A (en) Humanized anti-il-1r3 antibodies
CL2015002750A1 (es) Anticuerpos humanos pac1
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
IL240114A0 (en) B cell lineage based immunogen design with humanized animals
DK2814843T3 (da) IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
IL245306A0 (en) Compositions and methods for producing genetically modified animals
EP2970860A4 (en) Genetically modified bacteria